|
 Data from the so-called SUMMIT study, designed to show GSK's Breo
can prolong lives of patients with chronic lung disease, are
expected as early as next month, nine years after a similar study
with GSK's older drug Advair failed by a whisker.
This time GSK reckons it has a better chance, since the new trial,
with 16,500 patients, has more statistical power than the
6,100-patient Advair trial, known as TORCH. GSK has also chosen
higher-risk patients with heart issues for the new study.
At present, inhaled drugs such as Breo that combine a steroid and a
long-acting beta agonist (LABA) are known to help patients breath
more easily but their effect on survival is unclear.
If it succeeds, Breo would be the first drug to show a survival
benefit in patients with chronic obstructive pulmonary disease (COPD),
potentially turning around its fortunes.
While Breo was approved for COPD in 2013 and won a U.S. green light
for asthma in April, it has been slow to take off commercially.
Sometimes known as "son of Advair", once-a-day Breo has a dosing
advantage over twice-daily Advair. But the market for inhaled lung
drugs is fiercely competitive and Breo has struggled at a time when
GSK has been forced to cut Advair prices.
HSBC analyst Stephen McGarry thinks Breo could eventually achieve
peak annual sales of $5.0 billion if SUMMIT succeeds, or $1.8
billion if it fails.
Other analysts are more cautious and the current consensus is for
sales of $1.55 billion in 2020, according to Thomson Reuters
Cortellis.
GSK's partner Theravance is entitled to royalties of 15 percent on
the first $3 billion of annual sales and 5 percent beyond that.
[to top of second column] |
Britain's GSK has been a world leader in respiratory medicine since
launching the Ventolin inhaler back in 1969, but weak sales in
recent quarters are a mounting concern for its investors.
Courtney Crimm, a pulmonologist who oversees the SUMMIT trial at GSK,
believes a successful result would oblige doctors to rethink
prescribing strategies.
"If this study is positive, it could lead to a paradigm shift," he
told Reuters, noting that 50 to 70 percent of COPD patients also
have cardiovascular risk factors.
Furthermore, because SUMMIT recruited patients with "moderate" COPD
it might prompt wider use of the medicine in patients with less
severe breathing difficulties, he said.
Current medical guidelines recommend steroid and LABA combinations
only for people with more severe breathing problems. Those who are
less seriously affected are often given an alternative drug such as
Pfizer and Boehringer Ingelheim's Spiriva.
(Editing by Mark Potter)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
